Intellikine is focused on the R&a;D of orally available small molecule drugs targeting the PI3K/mTOR pathway.
Business Model:
Revenue: $17M
Employees: 51-200
Intellikine was acquired by
Takeda.
The acquisition happend on 2011-12-21.
Details of the transaction were not public
Address: 40 Landsdowne Street
City: Cambridge
State: MA
Zip: 02139
Country: US
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.
Contact Phone:
+18003675690
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2007 | Series B | 1 | $30M |
Sofinnova Investments Sofinnova Investments Sofinnova Investments Sofinnova Investments |
7/2009 | Series B | 6 | $51M |
U.S. Venture Partners Biogen Idec Abingworth Novartis Venture Fund CMEA Capital Sofinnova Investments U.S. Venture Partners Biogen Idec Abingworth Novartis Venture Fund CMEA Capital Sofinnova Investments |
10/2011 | Venture Round | $4M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|